PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+18.83%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$2.67B
AUM Growth
+$2.67B
(-5.5%)
Cap. Flow
-$524M
Cap. Flow
% of AUM
-19.65%
Top 10 Holdings %
Top 10 Hldgs %
54.89%
Holding
105
New
17
Increased
12
Reduced
35
Closed
21
Top Buys
| 1 |
Ascendis Pharma
ASND
|
$166M |
| 2 |
OMDA
Omada Health, Inc. Common Stock
OMDA
|
$44.4M |
| 3 |
Roivant Sciences
ROIV
|
$37.5M |
| 4 |
CAI
Caris Life Sciences, Inc. Common Stock
CAI
|
$29.3M |
| 5 |
Neurocrine Biosciences
NBIX
|
$19.5M |
Top Sells
| 1 |
Lyra Therapeutics
LYRA
|
$112M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$104M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$99.9M |
| 4 |
Soleno Therapeutics
SLNO
|
$90.2M |
| 5 |
Amicus Therapeutics
FOLD
|
$80.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Viking Therapeutics
VKTX
$3.04B
| $10.1M | 0.37% | 380,700 -128,305 | -25% | -$3.4M |
|
52
Ultragenyx Pharmaceutical
RARE
$2.89B
| $9.82M | 0.36% | +270,000 | New | +$9.82M |
|
53
Kymera Therapeutics
KYMR
$2.95B
| $9.17M | 0.34% | +210,106 | New | +$9.17M |
|
54
Nautilus Biotechnolgy
NAUT
$85.9M
| $9.13M | 0.34% | 12,594,211 | – | – |
|
55
Penumbra
PEN
$10.6B
| $8.42M | 0.31% | +32,797 | New | +$8.42M |
|
|
CBIO
56
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $7.32M | 0.27% | +453,686 | New | +$7.32M |
|
57
Aquestive Therapeutics
AQST
$456M
| $7.25M | 0.27% | 2,190,420 -1,536,788 | -41% | -$5.09M |
|
58
Janux Therapeutics
JANX
$1.37B
| $6.76M | 0.25% | 292,686 -677,726 | -70% | -$15.7M |
|
|
AVR
59
Anteris Technologies Global Corp. Common Stock
AVR
$145M
| $6.46M | 0.24% | 1,705,130 -434,870 | -20% | -$1.65M |
|
60
Xenon Pharmaceuticals
XENE
$2.98B
| $6.28M | 0.23% | 200,791 -124,533 | -38% | -$3.9M |
|
61
Viridian Therapeutics
VRDN
$1.5B
| $6.26M | 0.23% | 447,507 -212,155 | -32% | -$2.97M |
|
62
Corvus Pharmaceuticals
CRVS
$428M
| $5.75M | 0.21% | +1,438,595 | New | +$5.75M |
|
|
SEPN
63
Septerna, Inc. Common Stock
SEPN
$539M
| $5.72M | 0.21% | +541,450 | New | +$5.72M |
|
64
Globus Medical
GMED
$8.27B
| $5.22M | 0.19% | +88,500 | New | +$5.22M |
|
65
enVVeno Medical
NVNO
$15.4M
| $5.13M | 0.19% | +1,284,966 | New | +$5.13M |
|
|
BBOT
66
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $4.23M | 0.16% | 398,000 | – | – |
|
|
IRD
67
Opus Genetics, Inc. Common Stock
IRD
$73.1M
| $4.07M | 0.15% | 4,325,000 | – | – |
|
|
CTNM
68
Contineum Therapeutics
CTNM
$293M
| $2.78M | 0.1% | 699,486 -741,763 | -51% | -$2.94M |
|
|
69
Lyra Therapeutics
LYRA
$11.5M
| $2.29M | 0.08% | 255,150 -12,502,412 | -98% | -$112M |
|
70
scPharmaceuticals
SCPH
$295M
| $1.91M | 0.07% | 500,000 | – | – |
|
71
Athira Pharma
ATHA
$15.3M
| $1.63M | 0.06% | 5,402,964 | – | – |
|
72
RAPT Therapeutics
RAPT
$188M
| $1.47M | 0.05% | 183,890 -4,235,057 | -96% | -$33.9M |
|
|
TRIB
73
Trinity Biotech
TRIB
$5.44M
| $1.16M | 0.04% | +1,790,000 | New | +$1.16M |
|
74
Forte Biosciences
FBRX
$137M
| $882K | 0.03% | +68,192 | New | +$882K |
|
75
Avalo Therapeutics
AVTX
$122M
| $697K | 0.03% | 139,667 -380,333 | -73% | -$1.9M |
|